A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer

被引：0
|
作者：
He, Wen-zhuo
Jiang, Chang
Yi, Jiahong
Xue, Ju
Yin, Zhao-feng
Dong, Wen-jing
Xia, Liang-Ping
机构：
[1] Sun Yat Sen Univ, Dept VIP Reg, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Peoples R China
[4] Zhongshan City Peoples Hosp, Zhongshan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3534
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Yosuke Horita
    Yasuhide Yamada
    Ken Kato
    Yoshinori Hirashima
    Kouhei Akiyoshi
    Kengo Nagashima
    Takako Nakajima
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    International Journal of Clinical Oncology, 2012, 17 : 604 - 609
  • [2] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Horita, Yosuke
    Yamada, Yasuhide
    Kato, Ken
    Hirashima, Yoshinori
    Akiyoshi, Kouhei
    Nagashima, Kengo
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 604 - 609
  • [3] Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3
    Weiss, Lena
    Stintzing, Sebastian
    Modest, Dominik Paul
    von Weikersthal, Ludwig
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Moehler, Markus H.
    Scheithauer, Werner
    Held, Swantje
    Miller-Phillips, Lisa
    Stahler, Arndt
    Jung, Andreas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Suzuki, Takeshi
    Shinozaki, Eiji
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Ichimura, Takashi
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
  • [5] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [6] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Takeshi Suzuki
    Eiji Shinozaki
    Hiroki Osumi
    Izuma Nakayama
    Yumiko Ota
    Takashi Ichimura
    Mariko Ogura
    Takeru Wakatsuki
    Akira Ooki
    Daisuke Takahari
    Mitsukuni Suenaga
    Keisho Chin
    Kensei Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 307 - 313
  • [7] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    Surgery Today, 2011, 41 : 1067 - 1074
  • [8] Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
    Xu, Yun
    Wu, Yuchen
    Dai, Yuedi
    Ji, Xiaopin
    Cui, Zhe
    Zhu, Xiaodong
    Xu, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 151 - 151
  • [9] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
    Denda, Tadamichi
    Sakai, Daisuke
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Sunaga, Yoshinori
    Ziti-Ljajic, Samira
    Brillac, Claire
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (03) : 1032 - 1043
  • [10] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345